These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15246846

  • 1. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM.
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [Abstract] [Full Text] [Related]

  • 2. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
    Löschmann PA, De Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T.
    Exp Neurol; 2004 May; 187(1):86-93. PubMed ID: 15081591
    [Abstract] [Full Text] [Related]

  • 3. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR.
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [Abstract] [Full Text] [Related]

  • 4. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM.
    Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM.
    Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 12. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ.
    Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
    [Abstract] [Full Text] [Related]

  • 13. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
    Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG.
    Neuropharmacology; 2005 Mar; 48(4):503-16. PubMed ID: 15755478
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH, Henry B, Hill M, Crossman A, Brotchie J.
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [Abstract] [Full Text] [Related]

  • 16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K, Inoue T, Itoh T.
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.